Osterweis Capital Management Inc. increased its stake in shares of Audentes Therapeutics Inc (NASDAQ:BOLD) by 2.6% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 115,790 shares of the biotechnology company’s stock after acquiring an additional 2,950 shares during the quarter. Osterweis Capital Management Inc. owned approximately 0.27% of Audentes Therapeutics worth $4,584,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently bought and sold shares of BOLD. Redmile Group LLC grew its position in Audentes Therapeutics by 70.3% during the 2nd quarter. Redmile Group LLC now owns 2,228,656 shares of the biotechnology company’s stock worth $85,157,000 after acquiring an additional 920,130 shares during the last quarter. BlackRock Inc. grew its position in Audentes Therapeutics by 25.4% during the 2nd quarter. BlackRock Inc. now owns 2,458,171 shares of the biotechnology company’s stock worth $93,925,000 after acquiring an additional 497,767 shares during the last quarter. Partner Fund Management L.P. bought a new position in Audentes Therapeutics during the 2nd quarter worth approximately $16,254,000. Nexthera Capital LP bought a new position in Audentes Therapeutics during the 2nd quarter worth approximately $9,228,000. Finally, Victory Capital Management Inc. grew its position in Audentes Therapeutics by 35.1% during the 2nd quarter. Victory Capital Management Inc. now owns 739,241 shares of the biotechnology company’s stock worth $28,246,000 after acquiring an additional 191,950 shares during the last quarter. Institutional investors and hedge funds own 84.48% of the company’s stock.

Shares of BOLD stock opened at $23.34 on Thursday. The company has a market capitalization of $998.52 million, a PE ratio of -6.86 and a beta of 1.89. Audentes Therapeutics Inc has a fifty-two week low of $19.62 and a fifty-two week high of $46.18.

Audentes Therapeutics (NASDAQ:BOLD) last issued its quarterly earnings data on Tuesday, November 6th. The biotechnology company reported ($0.97) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.88) by ($0.09). During the same period in the previous year, the company posted ($0.88) earnings per share. On average, equities research analysts anticipate that Audentes Therapeutics Inc will post -3.42 earnings per share for the current year.

In related news, Director Louis G. Lange sold 33,000 shares of Audentes Therapeutics stock in a transaction that occurred on Monday, September 24th. The stock was sold at an average price of $37.38, for a total transaction of $1,233,540.00. Following the sale, the director now directly owns 365,999 shares in the company, valued at $13,681,042.62. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Suyash Prasad sold 10,000 shares of Audentes Therapeutics stock in a transaction that occurred on Monday, October 1st. The shares were sold at an average price of $36.88, for a total value of $368,800.00. Following the sale, the vice president now owns 100 shares in the company, valued at $3,688. The disclosure for this sale can be found here. Over the last quarter, insiders sold 101,039 shares of company stock worth $3,465,020. Corporate insiders own 6.60% of the company’s stock.

Several research firms recently issued reports on BOLD. JPMorgan Chase & Co. assumed coverage on Audentes Therapeutics in a research report on Sunday. They set an “overweight” rating and a $23.91 price target on the stock. ValuEngine lowered Audentes Therapeutics from a “buy” rating to a “hold” rating in a research report on Monday, November 12th. Raymond James reiterated a “hold” rating on shares of Audentes Therapeutics in a research report on Wednesday, November 7th. B. Riley lifted their price objective on Audentes Therapeutics from $20.00 to $21.00 and gave the stock a “sell” rating in a research report on Wednesday, November 7th. Finally, HC Wainwright set a $33.00 price objective on Audentes Therapeutics and gave the stock a “buy” rating in a research report on Wednesday, November 7th. Two research analysts have rated the stock with a sell rating, eight have given a hold rating and five have assigned a buy rating to the company. The company presently has an average rating of “Hold” and a consensus target price of $35.49.

ILLEGAL ACTIVITY WARNING: This article was first posted by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this article on another domain, it was stolen and reposted in violation of US and international copyright & trademark law. The legal version of this article can be read at https://theolympiareport.com/2018/12/06/osterweis-capital-management-inc-buys-2950-shares-of-audentes-therapeutics-inc-bold.html.

Audentes Therapeutics Profile

Audentes Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients suffering from diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT982, which is in preclinical studies for the treatment of pompe disease; and AT307 that is in preclinical studies to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia.

Featured Story: Google Finance Portfolio Tips and Tricks

Want to see what other hedge funds are holding BOLD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Audentes Therapeutics Inc (NASDAQ:BOLD).

Institutional Ownership by Quarter for Audentes Therapeutics (NASDAQ:BOLD)

Receive News & Ratings for Audentes Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.